18º Congresso Brasileiro de Neurologia Infantil

Dados do Trabalho



Apresentação do caso

Objective: to report a case of a metabolic disease of the urea cycle - hyperargininemia, which mimics spastic cerebral palsy, in addition to reviewing the medical literature.

Description: female, six-year-old patient, with no risk factors for brain injury, presented with spastic paraparesis, compromising gait, associated with cognitive and language impairment. Brain MRI showed cerebral atrophy.
The initial diagnosis of spastic diplegic cerebral palsy, GMFCS IV, was excluded 3 years later, considering the clinical evolution and the amino acid profile by mass spectrometry, which showed an increase in plasma arginine concentration, compatible with the diagnosis of hyperargininemia. Sequencing in the ARG1 gene confirmed 2 pathogenic variants.


Hyperargininemia is a rare, autosomal recessive metabolic disorder caused by an inherited deficiency of hepatocyte arginase due to a defect in the ARG1 gene. Arginase is the final enzyme in the urea cycle that catalyzes the hydrolysis of arginine to ornithine and urea . This genetic disorder is caused by more than 40 mutations found throughout the ARG1 gene, resulting in partial or complete loss of enzyme function.

With the application of liquid chromatography-tandem mass spectrometry in selective screening and neonatal screening for inborn errors of metabolism, a an increasing number of patients with argininemia are detected in the asymptomatic or early stages

Early diagnosis and a protein-restricted diet with citrulline and benzoate supplements may contribute to improving the patient's prognosis.

Comentários finais

Confirmation of a genetic diagnosis has relevant implications for the patient and family, and some specific metabolic conditions may improve symptoms and developmental outcome. Genetic counseling can prevent a recurrence of the disease in the family and provide information to other members at risk.

Several genetic problems can have clinical features that mimic cerebral palsy. It is essential to insist on the search for an accurate etiological diagnosis, especially among patients who do not have risk factors that justify the neurological condition.

Referências (se houver)

1. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D; Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005 aug;47(8): 571–576. doi: 10.1017/s001216220500112x. PMID: 16108461.
2. Cardoso ML, Martins E, Vasconcelos R, Vilarinho L, Rocha J. Identification of a novel R21X mutation in the liver-type arginase gene (ARG1) in four Portuguese patients with argininemia. Hum Mutat. 1999 Oct;14(4):355-356. doi: 10.1002/(SICI)1098-1004(199910)14:4<355::AID-HUMU20>3.0.CO;2-I. PMID: 10502833.
3. Carvalho DR, Brand GD, Brum JM, Takata RI, Speck-Martins CE, Pratesi R. Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes. Gene. 2012 Nov 1;509(1):124-130. doi: 10.1016/j.gene.2012.08.003. Epub 2012 Aug 16. PMID: 22959135.
4. Huang Y, Sharma R, Feigenbaum A, Lee C, Sahai I, Sanchez Russo R, Neira J, Brooks SS, Jackson KE, Wong D, Cederbaum S, Lacbawan FL, Rowland CM, Tanpaiboon P, Salazar D. Arginine to ornithine ratio as a diagnostic marker in patients with positive newborn screening for hyperargininemia. Mol Genet Metab Rep. 2021 Mar 3;27:100735. doi: 10.1016/j.ymgmr.2021.100735. PMID: 33732618; PMCID: PMC7937551.
5. Bakirtzis C, Smyrni N, Afrantou T, Boziki MK, Grigoriadis N. Spastic gait, intellectual disability and seizures due to a rare mutation causing hyperargininemia. Clin Neurol Neurosurg. 2021 Sep;208:106895. doi: 10.1016/j.clineuro.2021.106895. Epub 2021 Aug 14. PMID: 34419780.
6. Dorum S, Havalı C. Case series of arginase 1 deficiency: expanding the spectrum in hyperargininemia. Pediatr Int. 2022 Jan;64(1):e14945. doi: 10.1111/ped.14945. PMID: 34343381.
7. Diaz GA, Schulze A, McNutt MC, Leão-Teles E, Merritt JL 2nd, Enns GM, Batzios S, Bannick A, Zori RT, Sloan LS, Potts SL, Bubb G, Quinn AG. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2021 Jul;44(4):847-856. doi: 10.1002/jimd.12343. Epub 2021 Jan 26. PMID: 33325055; PMCID: PMC8359196.
8. Nakajima H, Fukuhara S. Two Japanese siblings with arginase-1 deficiency identified using a novel frameshift mutation of ARG1 (p.Lys41Thrfs∗2). J Pediatr Endocrinol Metab. 2021 Oct 18;35(1):125-129. doi: 10.1515/jpem-2021-0436. PMID: 34653322.
9. Keshavan N, Wood M, Alderson LM, Cortina-Borja M, Skeath R, McSweeney M, Dixon M, Cleary MA, Footitt E, Batzios S. Clinical status, biochemical profile and management of a single cohort of patients with arginase deficiency. JIMD Rep. 2021 Dec 30;63(2):123-130. doi: 10.1002/jmd2.12266. PMID: 35281666; PMCID: PMC8898719.
10. Schlune A, Vom Dahl S, Häussinger D, Ensenauer R, Mayatepek E. Hyperargininemia due to arginase I deficiency: the original patients and their natural history, and a review of the literature. Amino Acids. 2015 Sep;47(9):1751-1762. doi: 10.1007/s00726-015-2032-z. Epub 2015 Jun 27. PMID: 26123990.

Palavras Chave

Hyperargininemia, spastic paraparesis, cerebral palsy

Fonte de Fomento (se houver)


Declaração de conflito de interesses de TODOS os autores

There is no conflict of interest


Erros inatos do metabolismo